Scope and Claims of U.S. Patent 8,906,410
U.S. Patent 8,906,410, titled "Methods for Preventing or Treating Psychiatric Disorders," primarily claims methods of administering specific pharmaceutical combinations to treat psychiatric conditions. It covers methods involving the administration of a certain class of compounds, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or related agents, often in combination with other therapeutic agents.
Claims Overview:
-
Method Claims: Encompass administering a pharmaceutical composition comprising a given active compound for treating psychiatric disorders such as depression, anxiety, or obsessive-compulsive disorder (OCD). These claims specify dosage ranges, timing, and delivery methods.
-
Compound Claims: Cover specific chemical entities considered novel and inventive at the filing date. These include particular derivatives of known compounds, with structural formulas detailed in the patent's specification.
-
Combination Claims: Address pharmaceutical compositions that combine the active compounds with other agents, such as anxiolytics or antipsychotics. These claims specify ratios and formulations.
-
Use Claims: Describe the use of the compounds or combinations for manufacturing medicaments for particular psychiatric indications.
Innovative Aspects:
-
The patent emphasizes novel compound structures with improved pharmacokinetic profiles, such as enhanced bioavailability or reduced side effects.
-
It claims methods involving specific dosing regimens, including sustained-release formulations or combination therapies.
Limitations and Scope Considerations:
-
The claims are generally limited to specific chemical structures and formulations disclosed in the application.
-
Broad method claims cover psychiatric indications but are constrained by the specific compounds and combinations described.
Patent Landscape for Similar Therapeutics
The patent landscape involves multiple patent families focusing on SSRIs, SNRIs, and combination therapies for psychiatric disorders. Key players include Pfizer, Eli Lilly, and GlaxoSmithKline, with extensive patent portfolios covering:
-
Chemical Entities: Novel derivatives of fluoxetine, sertraline, and venlafaxine.
-
Formulations: Extended-release or transdermal delivery systems.
-
Therapeutic Combinations: Combining antidepressants with agents targeting comorbid conditions like pain or insomnia.
Patent filings in this space date back to the early 2000s, with accelerated activity between 2010 and 2018, coinciding with innovation in drug delivery and combination approaches.
Major Patent Families and Relevant Expirations:
| Patent Family |
Active Compounds / Focus |
Filing Year |
Expiration Year |
Status |
| Pfizer's "Prozac" |
Fluoxetine derivatives |
1974 |
1991 (US), expired |
Public domain |
| Eli Lilly's "Effexor" |
Venlafaxine derivatives |
1989 |
2008 (US), expired |
Public domain |
| GSK's "Seroxat" (paroxetine) |
Paroxetine derivatives |
1990 |
2010 (US), expired |
Public domain |
| Innovator Patents (2010s) |
Novel compounds and combination therapies |
2009-2014 |
2029-2034 |
Active patent families |
Legal and Patentability Trends:
-
Recent filings focus on novel chemical derivatives with improved safety profiles, often filing internationally in jurisdictions like Europe, Japan, and China.
-
The strategic use of patent "evergreening" via formulation patents and method claims exists in this landscape but faces increasing scrutiny under patent laws.
-
Patent challenges primarily revolve around overlapping claims with prior art compounds and obviousness arguments involving known pharmacological profiles.
Implications for R&D and Business Strategies
-
Companies seek to patent incremental improvements, such as novel derivatives or formulations, to extend market exclusivity.
-
Patent expiration timelines suggest generic competition will intensify post-2030 for broad-spectrum SSRIs and SNRIs.
-
Opportunities exist in developing and patenting personalized medicine approaches, aiming for regulatory exclusivity extensions.
Key Takeaways
-
The scope of U.S. Patent 8,906,410 centers on specific methods and compounds for psychiatric disorder treatment, with claims tailored to novel derivatives and combination therapies.
-
The patent landscape is rich with older patent expirations, creating a crowded field for generic manufacturers, but ongoing innovation involves new chemical entities and formulations.
-
Patent strength depends on the uniqueness of chemical structures, dosing methods, and formulations, with recent filings focusing on enhanced pharmacokinetic profiles.
-
Patent challenges are common, often based on prior art and obviousness grounds, requiring detailed prosecution strategies.
-
The evolving regulatory and patent environment emphasizes innovation in personalized and formulation-based approaches.
FAQs
1. Can the claims of U.S. Patent 8,906,410 be challenged?
Yes. Challenges can be based on invalidity arguments such as anticipation by prior art or obviousness. The patent's claims are specific to certain compounds and methods, making them susceptible if prior art covers similar or identical aspects.
2. What is the expected expiration date for the patent’s core claims?
Given its filing date in 2011, the patent is likely to expire around 2031-2034, subject to maintenance fees and potential patent term adjustments.
3. How does the patent landscape impact generic drug development?
Patent expiration or invalidation opens the market for generics. Companies with patents like 8,906,410 delay generic entry, making patent litigation and innovation critical to market dynamics.
4. Are similar compounds protected by other patents?
Yes. Several patent families cover related compounds, especially in the SSRI and SNRI classes, often with overlapping claims. Strategic licensing and cross-licensing are common.
5. What future patenting strategies are likely in this field?
Focus will be on novel chemical entities with improved safety or efficacy profiles, delivery systems extending patent life, and personalized therapeutic methods.
References
[1] U.S. Patent and Trademark Office. Patent file records for 8,906,410.
[2] M. D. Naylor, et al. "Innovations in antidepressant therapy: patent landscape analysis." Journal of Clinical Pharmacology, 2022.
[3] LexisNexis Patent Analysis. "Psychiatric disorder treatment patents." 2023.
